Browsing WoS İndeksli Yayınlar Koleksiyonu by Author "Paksoy, Nil"

Now showing items 1-1 of 1

The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

Kilickap, Saadettin; Paksoy, Nil; Bilgin, Burak; Sakin, Abdullah; Ozcan, Erkan; Tatli , Ali Murat; Hizal, Mutlu; Paksoy, Nail; Kahraman, Sedat (Springer, 2022)

Introduction: Alectinib is an effective second-generation ALK tyrosine kinase inhibitor (TKI) used in the first-line treatment of patients with advanced ALK-positive NSCLC. Recent studies demonstrated that the percentage ...